Horizons in Cancer Research. Volume 45.

By: Watanabe, Hiroto S
Series: Horizons in Cancer Research: Publisher: Hauppauge : Nova Science Publishers, Incorporated, 2011Copyright date: ©2011Description: 1 online resource (322 pages)Content type: text Media type: computer Carrier type: online resourceISBN: 9781620819081Subject(s): CancerGenre/Form: Electronic books. Additional physical formats: Print version:: Horizons in Cancer Research. Volume 45DDC classification: 616.994 LOC classification: RC261.A1 -- H67 2011ebOnline resources: Click to View
Contents:
Intro -- Contents -- Preface -- Chapter I -- Paclitaxel: Chemotherapy and Neurotoxicity - The Two Sides of the Coin -- Alessia Chiorazzi -- Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Monza, Italy -- 1. Abstract -- 2. Introduction -- A. History -- B. Mechanism of Action -- C. Pharmacodynamics -- D. Pharmacokinetics -- 3. Neurotoxicity in Clinical Practice -- A. Symptoms and Signs -- B. Clinical Trials -- C. Treatment of Paclitaxel-Induced Peripheral Neuropathy -- 4. In Vitro Studies -- 5. In Vivo Studies -- A. Rat Models of Peripheral Neurotoxicity Induced by Paclitaxel -- B. Mice Models of Peripheral Neurotoxicity Induced by Paclitaxel -- C. Paclitaxel-Induced Morphological Alterations in the Peripheral Nervous System -- 6. Neuroprotection: Pre-Clinical Models and Clinical Trials -- A. Antioxidants -- Alpha Lipoic Acid -- Vitamin E -- Resveratol -- B. Growth Factors -- Nerve Growth Factor -- Leukemia Inhibitory Factor -- Vascular Endothelial Growth Factor -- Erythropoietin -- C. Detoxicant -- Amifostine -- D. Other Compounds -- Olesoxime -- Geldanamycin and Radicicol -- Acetyl-L-Carnitine -- Glutamine -- Conclusion -- Abbreviations -- References -- Chapter II -- Proteomics in the Discovery of Biomarkers of Chemoresistance: The Current Status of Paclitaxel Resistance in Human Epithelial Ovarian Cancer -- M. Di Michele1, L. Cicchillitti2, A. Della Corte1, S. Marcone1, M. D'Imperio,1, C. Ferlini2, G. Scambia2, M.B. Donati1, and D. Rotilio1 -- 1(RE ARTU) Research Laboratories -- 2Department of Oncology, John Paul II Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy -- Abstract -- 1. Introduction -- 2. Proteomics Methods for Biomarker Discovery -- 2.1. Gel-Based Methods -- 2.1.1. 2D-PAGE -- 2.1.2. DIGE -- 2.1.3. Gel Staining.
2.1.4. Protein Identification by Mass Spectrometry -- 2.2. Gel-Free Methods -- 2.2.1. LC-MS/MS -- 2.2.2. Stable Isotope Labeling -- 2.2.3. Peptide Profiling -- 2.3. Post-Translational Modifications (PTMs) -- 2.3.1. Phosphoproteomics -- 2.3.2. Glycoproteomics -- 2.4. Bioinformatics Tools -- 3. Proteomics to Identify Biomarkers in Cancer Chemoresistance -- 4. Paclitaxel Resistance in Ovarian Cancer -- by a Proteomic Approach -- 4.1. Ovarian Cancer -- 4.2. Paclitaxel Resistance -- 4.3. Current Status of Proteomic Research to Study Paclitaxel Resistance in Ovarian Cancer -- Conclusion -- References -- Chapter III -- Macromolecules as Paclitaxel Carriers: From Chemical Considerations to Clinical Applications -- Franco Dosio1 and Daniela Gastaldi2 -- University of Torino, Italy -- 1 Department of Drug Sciences and Technology -- 2 Department of Analytical Chemistry, v. Giuria 5-9, Torino, Italy -- Abstract -- 1. Introduction -- 2. Natural Macromolecules as Paclitaxel Carriers -- 2.1. Heparin Conjugates -- 2.2. Chitosan Conjugates -- 2.3. Hyaluronic Acid Conjugates -- 2.4. Dextran Conjugates -- 2.5. Protein and Peptide Conjugates -- 2.6. Monoclonal Antibody Derivatives and Targeted Prodrugs -- 3. Conjugates Composed by Paclitaxel and Synthetic Polymers -- 3.1. Poly (Ethylene Glycol) Conjugates -- 3.2. Polyaminoacid Conjugates -- 3.3. N-(2-Hydroxypropyl) Methacrylamide Conjugates -- 3.4. Dendrimeric Conjugates -- Conclusion -- References -- Chapter IV -- Paclitaxel Crystals: Molecular Interactions, Nucleation and Growth, and Possible Implications on Cell Studies -- Javier S. Castro1, 2*, Pierre A. Deymier1 and Bartosz Trzaskowski3 -- 1 Department of Materials Science and Engineering, University of Arizona, -- AZ, USA -- 2. Autonomous University of Juarez City (UACJ), Juarez City, Chih. Mexico.
3 Materials and Process Simulation Center, California Institute of Technology, -- CA, USA -- Abstract -- 1. Introduction -- 2. Binding Affinity of Fluorochromes and Fluorescent Proteins to Paclitaxel Crystals -- 2.1. Experimental Procedures and Results -- 2.2.1. Electron Microscopy Characterization of Paclitaxel Crystals -- 2.3. Computational Analysis -- 2.3.1. Paclitaxel Crystal Structure -- 2.3.2. Binding Affinity of Tubulin to Paclitaxel Crystals -- 2.3.3. Binding Affinity of Fluorochromes to Paclitaxel Crystals -- 3. Nucleation and Growth of Paclitaxel Crystals in Aqueous Solutions and Gels: Effect of Tubulin Proteins -- 3.1. Spherulitic and Needle-Like Crystals Growth -- 3.2. Homogeneous Crystallization of Paclitaxel -- 3.3. Heterogeneous Nucleation of Paclitaxel in Tubulin-Containing Aqueous Solutions -- 3.4. Effect of Tubulin Concentration on Crystallization of Paclitaxel in Aqueous Liquid Environments -- 3.5. Crystallization of Paclitaxel in Agarose Gels -- 3.5.1. Experiments Performed in a Circular Cuvette -- 3.5.2. Experiments Performed in a Rectangular Column -- 3.6. Paclitaxel-Tubulin Binding Site -- 4. Possible Implications on Cell Studies -- Conclusions -- References -- Chapter V -- Second Primary Cancer in Children and Adults: A Comparison -- Carmen Mejia1, Alberto Serrano-Olvera2 and Lena Ruiz-Azuara3* -- 1 Instituto de Investigaciones Biomédicas, UNAM -- 2Subdirección de Investigación Clínica del Instituto Nacional de Cáncerología y, Departamento de Oncología Médica del Centro ABC, México -- 3Facultad de Química, UNAM -- Abstract -- Introduction -- Factors Related to the Development of Second Primary Cancer -- Genetic Syndromes -- Lifestyle and Environmental Factors -- Chemotherapy and Tamoxifen -- Tamoxifen -- Radiotherapy -- Possible Causes of Secondary Tumors in Childhood -- Most Frequent Secondary Childhood Neoplasm.
Rare Neoplasms Following Primary Tumors in Children -- Epidemiology of the Second Primary Cancers in Adults -- Hodgkin's Lymphoma -- Testicular Cancer -- Cervical-Uterine Cancer -- Breast Cancer -- Prevention of a Second Malignancy -- Conclusion -- Grant Sponsors -- References -- Chapter VI -- Critical Evaluation of the Use of CD133 as a Cancer Stem Cell Marker in Solid Tumors -- Scott Bidlingmaier1, Xiaodong Zhu1, Yue Liu1 and Bin Liu1,2, * -- 1Department of Anesthesia, -- 2Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, CA, USA -- Abstract -- The CD133 Molecule, AC133 and AC141 Antibodies, and Stem and Progenitor Cell Populations -- CD133 Expression is Often Correlated with,But Not Required, for Brain Tumor Initiation -- CD133 as a CSC Marker in Other Solid Tumors -- Issues Concerning Commonly Used CD133 Antibodies (AC133 and AC141) -- Oxygen Levels Modulate CD133 Expression -- Cell Cycle Regulation of CD133 Expression -- CD133 Expression as a Prognostic Marker -- Functional Studies of the CD133 Molecule -- Evaluation of CD133 and Other Putative CSC Markers in the Context of the CSC Hypothesis -- Acknowledgments -- Abbreviations -- References -- Chapter VII -- Psychosocial Oncology -- Kevin Bumpers -- Emory University, Atlanta, Georgia, US -- Introduction -- Factors Leading to Cancer Disparities in the United States -- Cancer Incidence and Outcomes for African Americans -- African Americans and Treatment Delay -- Mistrust of the Healthcare System -- Means for Overcoming Barriers to Equitable Healthcare -- The Role and Impact of Oncology Social Work in Overcoming Healthcare Disparities -- Social Workers and Improving Cancer Outcomes -- Barriers to Oncology Social Work -- Steps to Improving Barriers to Oncology Social Work -- Conclusion -- References -- Chapter VIII.
Brain Metastases: Symptoms, Diagnosis and Treatment -- Semra Paydas* -- Cukurova University faculty of Medicine, Department of Oncology -- Adana, Turkey -- Introduction -- Clinical Presentation -- Diagnosis -- Therapeutic Options -- Whole Brain Irradiatıon Therapy (WBI) -- WBI in Combination with Temozolamide -- WBI in Combination with Stereotactic Surgery (SRS) or Stereotactic Radiotherapy (SRT) -- Surgery and Whole Brain Irradiation (WBI) -- Stereotactic Radiosurgery (SRS) -- Chemotherapy (CT) -- The Management of Brain Metastases in Special Tumors -- Breast Cancer -- Non Small Cell Lung Cancer -- Malignant Melanoma -- Leptomeningeal Metastases or Carcinomatous Meningitis or Leptomeningeal Carcinomatosis -- RTOG Neurologic Function Classification -- Targeted Treatment -- Management of Brain Edema and the Use of Steroids and Anticonvulsants -- Prognosis -- References -- Chapter IX -- Long-Term Recurrences and Second Tumors After Curative Surgery for Cancer of the Esophagus and Gastroesophageal Junction -- Andrés Sánchez-Pernaute*, Norman Jael Cervantes, -- Óscar Cano Valderrama, María Elia Pérez-Aguirre and Antonio José Torres García -- Abstract -- Introduction -- Patients and Method -- Results -- Conclusions -- Introduction -- Patients and Methods -- Results -- Long-Term Survivors -- Discussion -- References -- Chapter X -- Prophylactic Cranial Irradiation in Non-Small Cell Lung Cancer -- Hai-bo Sun and Si-yu Wang* -- Cancer Center of Sun Yat-sen University, -- Guangzhou, People's Republic of China -- Abstract -- Introduction -- Factors Associated with Brain Metastases -- 1. Chemotherapy -- 2. Stage -- 3. Histology and Age -- Treatment of Brain Metastases -- 1. Nonrandomized Study of PCI -- PCI in Patients with NSCLC -- 2. Randomized Stuies of PCI -- Toxicity of PCI -- PCI: When and How? -- Conclusion -- References -- Chapter XI.
Mitochondrial Dysfunction of AS-30D Rat Ascites Hepatoma Cells: Action of Zinc (II) and Sodium Selenite.
Item type Current location Call number Status Date due Barcode Item holds
Ebrary Ebrary Afghanistan
Available EBKAF-N00016072
Ebrary Ebrary Algeria
Available
Ebrary Ebrary Cyprus
Available
Ebrary Ebrary Egypt
Available
Ebrary Ebrary Libya
Available
Ebrary Ebrary Morocco
Available
Ebrary Ebrary Nepal
Available EBKNP-N00016072
Ebrary Ebrary Sudan

Access a wide range of magazines and books using Pressreader and Ebook central.

Enjoy your reading, British Council Sudan.

Available
Ebrary Ebrary Tunisia
Available
Total holds: 0

Intro -- Contents -- Preface -- Chapter I -- Paclitaxel: Chemotherapy and Neurotoxicity - The Two Sides of the Coin -- Alessia Chiorazzi -- Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Monza, Italy -- 1. Abstract -- 2. Introduction -- A. History -- B. Mechanism of Action -- C. Pharmacodynamics -- D. Pharmacokinetics -- 3. Neurotoxicity in Clinical Practice -- A. Symptoms and Signs -- B. Clinical Trials -- C. Treatment of Paclitaxel-Induced Peripheral Neuropathy -- 4. In Vitro Studies -- 5. In Vivo Studies -- A. Rat Models of Peripheral Neurotoxicity Induced by Paclitaxel -- B. Mice Models of Peripheral Neurotoxicity Induced by Paclitaxel -- C. Paclitaxel-Induced Morphological Alterations in the Peripheral Nervous System -- 6. Neuroprotection: Pre-Clinical Models and Clinical Trials -- A. Antioxidants -- Alpha Lipoic Acid -- Vitamin E -- Resveratol -- B. Growth Factors -- Nerve Growth Factor -- Leukemia Inhibitory Factor -- Vascular Endothelial Growth Factor -- Erythropoietin -- C. Detoxicant -- Amifostine -- D. Other Compounds -- Olesoxime -- Geldanamycin and Radicicol -- Acetyl-L-Carnitine -- Glutamine -- Conclusion -- Abbreviations -- References -- Chapter II -- Proteomics in the Discovery of Biomarkers of Chemoresistance: The Current Status of Paclitaxel Resistance in Human Epithelial Ovarian Cancer -- M. Di Michele1, L. Cicchillitti2, A. Della Corte1, S. Marcone1, M. D'Imperio,1, C. Ferlini2, G. Scambia2, M.B. Donati1, and D. Rotilio1 -- 1(RE ARTU) Research Laboratories -- 2Department of Oncology, John Paul II Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy -- Abstract -- 1. Introduction -- 2. Proteomics Methods for Biomarker Discovery -- 2.1. Gel-Based Methods -- 2.1.1. 2D-PAGE -- 2.1.2. DIGE -- 2.1.3. Gel Staining.

2.1.4. Protein Identification by Mass Spectrometry -- 2.2. Gel-Free Methods -- 2.2.1. LC-MS/MS -- 2.2.2. Stable Isotope Labeling -- 2.2.3. Peptide Profiling -- 2.3. Post-Translational Modifications (PTMs) -- 2.3.1. Phosphoproteomics -- 2.3.2. Glycoproteomics -- 2.4. Bioinformatics Tools -- 3. Proteomics to Identify Biomarkers in Cancer Chemoresistance -- 4. Paclitaxel Resistance in Ovarian Cancer -- by a Proteomic Approach -- 4.1. Ovarian Cancer -- 4.2. Paclitaxel Resistance -- 4.3. Current Status of Proteomic Research to Study Paclitaxel Resistance in Ovarian Cancer -- Conclusion -- References -- Chapter III -- Macromolecules as Paclitaxel Carriers: From Chemical Considerations to Clinical Applications -- Franco Dosio1 and Daniela Gastaldi2 -- University of Torino, Italy -- 1 Department of Drug Sciences and Technology -- 2 Department of Analytical Chemistry, v. Giuria 5-9, Torino, Italy -- Abstract -- 1. Introduction -- 2. Natural Macromolecules as Paclitaxel Carriers -- 2.1. Heparin Conjugates -- 2.2. Chitosan Conjugates -- 2.3. Hyaluronic Acid Conjugates -- 2.4. Dextran Conjugates -- 2.5. Protein and Peptide Conjugates -- 2.6. Monoclonal Antibody Derivatives and Targeted Prodrugs -- 3. Conjugates Composed by Paclitaxel and Synthetic Polymers -- 3.1. Poly (Ethylene Glycol) Conjugates -- 3.2. Polyaminoacid Conjugates -- 3.3. N-(2-Hydroxypropyl) Methacrylamide Conjugates -- 3.4. Dendrimeric Conjugates -- Conclusion -- References -- Chapter IV -- Paclitaxel Crystals: Molecular Interactions, Nucleation and Growth, and Possible Implications on Cell Studies -- Javier S. Castro1, 2*, Pierre A. Deymier1 and Bartosz Trzaskowski3 -- 1 Department of Materials Science and Engineering, University of Arizona, -- AZ, USA -- 2. Autonomous University of Juarez City (UACJ), Juarez City, Chih. Mexico.

3 Materials and Process Simulation Center, California Institute of Technology, -- CA, USA -- Abstract -- 1. Introduction -- 2. Binding Affinity of Fluorochromes and Fluorescent Proteins to Paclitaxel Crystals -- 2.1. Experimental Procedures and Results -- 2.2.1. Electron Microscopy Characterization of Paclitaxel Crystals -- 2.3. Computational Analysis -- 2.3.1. Paclitaxel Crystal Structure -- 2.3.2. Binding Affinity of Tubulin to Paclitaxel Crystals -- 2.3.3. Binding Affinity of Fluorochromes to Paclitaxel Crystals -- 3. Nucleation and Growth of Paclitaxel Crystals in Aqueous Solutions and Gels: Effect of Tubulin Proteins -- 3.1. Spherulitic and Needle-Like Crystals Growth -- 3.2. Homogeneous Crystallization of Paclitaxel -- 3.3. Heterogeneous Nucleation of Paclitaxel in Tubulin-Containing Aqueous Solutions -- 3.4. Effect of Tubulin Concentration on Crystallization of Paclitaxel in Aqueous Liquid Environments -- 3.5. Crystallization of Paclitaxel in Agarose Gels -- 3.5.1. Experiments Performed in a Circular Cuvette -- 3.5.2. Experiments Performed in a Rectangular Column -- 3.6. Paclitaxel-Tubulin Binding Site -- 4. Possible Implications on Cell Studies -- Conclusions -- References -- Chapter V -- Second Primary Cancer in Children and Adults: A Comparison -- Carmen Mejia1, Alberto Serrano-Olvera2 and Lena Ruiz-Azuara3* -- 1 Instituto de Investigaciones Biomédicas, UNAM -- 2Subdirección de Investigación Clínica del Instituto Nacional de Cáncerología y, Departamento de Oncología Médica del Centro ABC, México -- 3Facultad de Química, UNAM -- Abstract -- Introduction -- Factors Related to the Development of Second Primary Cancer -- Genetic Syndromes -- Lifestyle and Environmental Factors -- Chemotherapy and Tamoxifen -- Tamoxifen -- Radiotherapy -- Possible Causes of Secondary Tumors in Childhood -- Most Frequent Secondary Childhood Neoplasm.

Rare Neoplasms Following Primary Tumors in Children -- Epidemiology of the Second Primary Cancers in Adults -- Hodgkin's Lymphoma -- Testicular Cancer -- Cervical-Uterine Cancer -- Breast Cancer -- Prevention of a Second Malignancy -- Conclusion -- Grant Sponsors -- References -- Chapter VI -- Critical Evaluation of the Use of CD133 as a Cancer Stem Cell Marker in Solid Tumors -- Scott Bidlingmaier1, Xiaodong Zhu1, Yue Liu1 and Bin Liu1,2, * -- 1Department of Anesthesia, -- 2Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, CA, USA -- Abstract -- The CD133 Molecule, AC133 and AC141 Antibodies, and Stem and Progenitor Cell Populations -- CD133 Expression is Often Correlated with,But Not Required, for Brain Tumor Initiation -- CD133 as a CSC Marker in Other Solid Tumors -- Issues Concerning Commonly Used CD133 Antibodies (AC133 and AC141) -- Oxygen Levels Modulate CD133 Expression -- Cell Cycle Regulation of CD133 Expression -- CD133 Expression as a Prognostic Marker -- Functional Studies of the CD133 Molecule -- Evaluation of CD133 and Other Putative CSC Markers in the Context of the CSC Hypothesis -- Acknowledgments -- Abbreviations -- References -- Chapter VII -- Psychosocial Oncology -- Kevin Bumpers -- Emory University, Atlanta, Georgia, US -- Introduction -- Factors Leading to Cancer Disparities in the United States -- Cancer Incidence and Outcomes for African Americans -- African Americans and Treatment Delay -- Mistrust of the Healthcare System -- Means for Overcoming Barriers to Equitable Healthcare -- The Role and Impact of Oncology Social Work in Overcoming Healthcare Disparities -- Social Workers and Improving Cancer Outcomes -- Barriers to Oncology Social Work -- Steps to Improving Barriers to Oncology Social Work -- Conclusion -- References -- Chapter VIII.

Brain Metastases: Symptoms, Diagnosis and Treatment -- Semra Paydas* -- Cukurova University faculty of Medicine, Department of Oncology -- Adana, Turkey -- Introduction -- Clinical Presentation -- Diagnosis -- Therapeutic Options -- Whole Brain Irradiatıon Therapy (WBI) -- WBI in Combination with Temozolamide -- WBI in Combination with Stereotactic Surgery (SRS) or Stereotactic Radiotherapy (SRT) -- Surgery and Whole Brain Irradiation (WBI) -- Stereotactic Radiosurgery (SRS) -- Chemotherapy (CT) -- The Management of Brain Metastases in Special Tumors -- Breast Cancer -- Non Small Cell Lung Cancer -- Malignant Melanoma -- Leptomeningeal Metastases or Carcinomatous Meningitis or Leptomeningeal Carcinomatosis -- RTOG Neurologic Function Classification -- Targeted Treatment -- Management of Brain Edema and the Use of Steroids and Anticonvulsants -- Prognosis -- References -- Chapter IX -- Long-Term Recurrences and Second Tumors After Curative Surgery for Cancer of the Esophagus and Gastroesophageal Junction -- Andrés Sánchez-Pernaute*, Norman Jael Cervantes, -- Óscar Cano Valderrama, María Elia Pérez-Aguirre and Antonio José Torres García -- Abstract -- Introduction -- Patients and Method -- Results -- Conclusions -- Introduction -- Patients and Methods -- Results -- Long-Term Survivors -- Discussion -- References -- Chapter X -- Prophylactic Cranial Irradiation in Non-Small Cell Lung Cancer -- Hai-bo Sun and Si-yu Wang* -- Cancer Center of Sun Yat-sen University, -- Guangzhou, People's Republic of China -- Abstract -- Introduction -- Factors Associated with Brain Metastases -- 1. Chemotherapy -- 2. Stage -- 3. Histology and Age -- Treatment of Brain Metastases -- 1. Nonrandomized Study of PCI -- PCI in Patients with NSCLC -- 2. Randomized Stuies of PCI -- Toxicity of PCI -- PCI: When and How? -- Conclusion -- References -- Chapter XI.

Mitochondrial Dysfunction of AS-30D Rat Ascites Hepatoma Cells: Action of Zinc (II) and Sodium Selenite.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2019. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments for this item.

to post a comment.